Gene Therapy Update for Friedreich’s Ataxia What patients and families should know (March 2026) Who is Lexeo Therapeutics? Lexeo Therapeutics is a biotechnology company developing gene therapies for heart disease, including heart involvement caused by Friedreich’s ataxia (FA)—a major cause of illness and premature death in FA. What treatment is...

Researchers at The Neuro (Montreal Neurological Institute-Hospital) are currently evaluating a non-invasive electrical brain stimulation technique to temporarily relieve symptoms of Friedreich’s ataxia (FA). This international clinical study, conducted in Canada exclusively at The Neuro is exploring the use of transcranial direct current stimulation (tDCS) to reactivate brain circuits affected...

For Adolescent Patients and Parents/Caregivers of Pediatric Patients The BRAVE Study is evaluating a potential treatment option for Friedreich Ataxia. If your child has been diagnosed with Friedreich Ataxia (FA), they may be eligible for the BRAVE Study. About the BRAVE Study. The BRAVE Study is evaluating how safe a...

Thanks to yous upport and our partnership with Muscular Dystrophy Canada, we have funded two projects focused on Friedreich Ataxia (FA) this year ! We are thrilled to support clinical and translational research projects that focus on managing symptoms, healthcare assessments, understanding diagnosis and disease progression, enhancing care, discovering new...

The study is being conducted with multiple sites in the United States and Canada seeking to recruit approximately 9 participants aged 18-40 with a diagnosis of FA-associated cardiomyopathy. The study will be conducted by Dr. Antoine Duquette at the CHUM in Montreal. The choice of Montreal as a site reflects...

CIHR’s Institute of Genetics is planning a workshop to bring together patients living in Canada to help ensure patient and caregiver voices are heard and guide our future work. We will discuss best practices in patient engagement in genetics research, focusing on equity, diversity, and inclusion. We are looking for...

The National Ataxia Foundation today announced that the Centre hospitalier de l’Université de Montréal (CHUM) will be the first international clinical site to join the Clinical Research Consortium for the Study of Cerebellar Ataxia (CRC-SCA). The CRC-SCA is a group of clinical research sites across the United States actively enrolling...